These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
467 related articles for article (PubMed ID: 32279936)
21. Artificial Intelligence-Powered Assessment of Pathologic Response to Neoadjuvant Atezolizumab in Patients With NSCLC: Results From the LCMC3 Study. Dacic S; Travis WD; Giltnane JM; Kos F; Abel J; Hilz S; Fujimoto J; Sholl L; Ritter J; Khalil F; Liu Y; Taylor-Weiner A; Resnick M; Yu H; Hirsch FR; Bunn PA; Carbone DP; Rusch V; Kwiatkowski DJ; Johnson BE; Lee JM; Hennek SR; Wapinski I; Nicholas A; Johnson A; Schulze K; Kris MG; Wistuba II J Thorac Oncol; 2024 May; 19(5):719-731. PubMed ID: 38070597 [TBL] [Abstract][Full Text] [Related]
22. Pathological nodal disease defines survival outcomes in patients with lung cancer with tumour major pathological response following neoadjuvant chemotherapy. Corsini EM; Weissferdt A; Pataer A; Zhou N; Antonoff MB; Hofstetter WL; Mehran RJ; Rajaram R; Rice DC; Roth JA; Vaporciyan AA; Walsh GL; Cascone T; Heymach JV; Swisher SG; Sepesi B Eur J Cardiothorac Surg; 2021 Jan; 59(1):100-108. PubMed ID: 32864702 [TBL] [Abstract][Full Text] [Related]
23. Long term follow-up of neoadjuvant-adjuvant combination treatment of IIIA stage non-small-cell-lung cancer: results of neoadjuvant carboplatin/vinorelbine and carboplatin/paclitaxel regimens combined with selective adjuvant chemotherapy according to in-vitro chemoresistance test. Kolek V; Grygarkova I; Hajduch M; Klein J; Cwiertka K; Neoral C; Langova K; Mihal V Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2008 Dec; 152(2):259-66. PubMed ID: 19219217 [TBL] [Abstract][Full Text] [Related]
24. A novel histopathological evaluation method predicting the outcome of non-small cell lung cancer treated by neoadjuvant therapy: the prognostic importance of the area of residual tumor. Yamane Y; Ishii G; Goto K; Kojima M; Nakao M; Shimada Y; Nishiwaki Y; Nagai K; Kohrogi H; Ochiai A J Thorac Oncol; 2010 Jan; 5(1):49-55. PubMed ID: 20035185 [TBL] [Abstract][Full Text] [Related]
25. The predictive value of Yin X; Li J; Chen B; Liu K; Hu S Lung Cancer; 2023 Dec; 186():107389. PubMed ID: 37820538 [TBL] [Abstract][Full Text] [Related]
26. Efficacy and surgical safety of sequential surgical resection after pembrolizumab plus chemotherapy for initial unresectable stage IIIB non-small cell lung cancer. Zheng J; Li Y; Jin C; Ruan K; Sun K; Chen H; Wang M; Zhang S; Zhou J; Zhou J Lung Cancer; 2023 Oct; 184():107326. PubMed ID: 37579576 [TBL] [Abstract][Full Text] [Related]
27. Neoadjuvant immunotherapy combined with chemotherapy significantly improved patients' overall survival when compared with neoadjuvant chemotherapy in non-small cell lung cancer: A cohort study. Dai F; Wu X; Wang X; Li K; Wang Y; Shen C; Zhou J; Niu H; Deng B; Tan Q; Wang R; Guo W Front Oncol; 2022; 12():1022123. PubMed ID: 36353552 [TBL] [Abstract][Full Text] [Related]
28. Machine Learning-Based Prediction of Pathological Responses and Prognosis After Neoadjuvant Chemotherapy for Non-Small-Cell Lung Cancer: A Retrospective Study. Jiang Z; Li Q; Ruan J; Li Y; Zhang D; Xu Y; Liao Y; Zhang X; Gao D; Li Z Clin Lung Cancer; 2024 Jul; 25(5):468-478.e3. PubMed ID: 38719649 [TBL] [Abstract][Full Text] [Related]
29. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial. Betticher DC; Hsu Schmitz SF; Tötsch M; Hansen E; Joss C; von Briel C; Schmid RA; Pless M; Habicht J; Roth AD; Spiliopoulos A; Stahel R; Weder W; Stupp R; Egli F; Furrer M; Honegger H; Wernli M; Cerny T; Ris HB J Clin Oncol; 2003 May; 21(9):1752-9. PubMed ID: 12721251 [TBL] [Abstract][Full Text] [Related]
30. Surgical perspective in neoadjuvant chemoimmunotherapy for stage II-III non-small cell lung cancer. Hong T; Sun T; Zhang M; Liu X; Yuan Y; Dolo PR; Chen B; Zhang H Thorac Cancer; 2021 Oct; 12(20):2796-2802. PubMed ID: 34463034 [TBL] [Abstract][Full Text] [Related]
31. Pathologic complete response to preoperative chemotherapy predicts cure in early-stage non-small-cell lung cancer: combined analysis of two IFCT randomized trials. Mouillet G; Monnet E; Milleron B; Puyraveau M; Quoix E; David P; Ducoloné A; Molinier O; Zalcman G; Depierre A; Westeel V; J Thorac Oncol; 2012 May; 7(5):841-9. PubMed ID: 22722786 [TBL] [Abstract][Full Text] [Related]
32. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Cascone T; William WN; Weissferdt A; Leung CH; Lin HY; Pataer A; Godoy MCB; Carter BW; Federico L; Reuben A; Khan MAW; Dejima H; Francisco-Cruz A; Parra ER; Solis LM; Fujimoto J; Tran HT; Kalhor N; Fossella FV; Mott FE; Tsao AS; Blumenschein G; Le X; Zhang J; Skoulidis F; Kurie JM; Altan M; Lu C; Glisson BS; Byers LA; Elamin YY; Mehran RJ; Rice DC; Walsh GL; Hofstetter WL; Roth JA; Antonoff MB; Kadara H; Haymaker C; Bernatchez C; Ajami NJ; Jenq RR; Sharma P; Allison JP; Futreal A; Wargo JA; Wistuba II; Swisher SG; Lee JJ; Gibbons DL; Vaporciyan AA; Heymach JV; Sepesi B Nat Med; 2021 Mar; 27(3):504-514. PubMed ID: 33603241 [TBL] [Abstract][Full Text] [Related]
33. Copy number variations mediate major pathological response to induction chemo-immunotherapy in unresectable stage IIIA-IIIB lung cancer. Zeng L; Zhou Y; Zhang X; Xu Q; Zhou C; Zeng F; Jiang W; Wang Z; Deng L; Yang H; Liu L; Xiong Y; Zhang B; Yang N; Zhang Y Lung Cancer; 2023 Apr; 178():134-142. PubMed ID: 36858002 [TBL] [Abstract][Full Text] [Related]
34. CMTM1_v17 is associated with chemotherapy resistance and poor prognosis in non-small cell lung cancer. Si J; Zhang P; Tian D; Wang X; Ma Y; Zhang J; Wang L; Yang Y World J Surg Oncol; 2017 Jan; 15(1):34. PubMed ID: 28129775 [TBL] [Abstract][Full Text] [Related]
35. Maturation and abundance of tertiary lymphoid structures are associated with the efficacy of neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer. Sun X; Liu W; Sun L; Mo H; Feng Y; Wu X; Li C; Chen C; Li J; Xin Y; Zhang Z; Wang C; Zhang B; Yue D J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 37011953 [TBL] [Abstract][Full Text] [Related]
36. Different pathological response and histological features following neoadjuvant chemotherapy or chemo-immunotherapy in resected non-small cell lung cancer. Alì G; Poma AM; Di Stefano I; Zirafa CC; Lenzini A; Martinelli G; Romano G; Chella A; Baldini E; Melfi F; Fontanini G Front Oncol; 2023; 13():1115156. PubMed ID: 36845706 [TBL] [Abstract][Full Text] [Related]
37. Outcome of Patients With pN2 "Potentially Resectable" Nonsmall Cell Lung Cancer Who Underwent Surgery After Induction Chemotherapy. Spaggiari L; Casiraghi M; Guarize J; Brambilla D; Petrella F; Maisonneuve P; De Marinis F Semin Thorac Cardiovasc Surg; 2016 Summer; 28(2):593-602. PubMed ID: 28043483 [TBL] [Abstract][Full Text] [Related]
38. Real-world outcomes of immunotherapy-based neoadjuvant therapy in resectable non-small cell lung cancer. Shen J; Gu L; Qi Y; Yao Y; Lu S; Chen Z Front Immunol; 2023; 14():1268251. PubMed ID: 37818382 [TBL] [Abstract][Full Text] [Related]
39. A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Non-Small Cell Lung Cancer. Cascone T; Sepesi B; Lin HY; Kalhor N; Parra ER; Jiang M; Godoy MCB; Zhang J; Fossella FV; Tsao AS; Lam VK; Lu C; Mott FE; Simon GR; Antonoff MB; Mehran RJ; Rice DC; Behrens C; Weissferdt A; Moran C; Vaporciyan AA; Lee JJ; Swisher SG; Gibbons DL; Wistuba II; William WN; Heymach JV Clin Cancer Res; 2020 Jul; 26(14):3525-3536. PubMed ID: 32193228 [TBL] [Abstract][Full Text] [Related]
40. Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long-term results and associations with pathologic response. Machtay M; Lee JH; Stevenson JP; Shrager JB; Algazy KM; Treat J; Kaiser LR J Thorac Cardiovasc Surg; 2004 Jan; 127(1):108-13. PubMed ID: 14752420 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]